Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written consent to participate in the study~* Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions~* Male or female ≥ 40 years of age~* Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening~* Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA~* Kellgren-Lawrence (KL) Grade 2, 3 or 4 in the index knee based on X-ray performed during Screening~* Qualifying score for WOMAC A at Screening and Day 1/Baseline~* Index knee pain for \>15 days over the last month (as reported by the patient)~* Body mass index (BMI) ≤ 40 kg/m2~* Ambulatory and in good general health~* Willingness to abstain from use of protocol-restricted medications during the study~Exclusion Criteria:~* Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease~* History of infection in the index knee joint~* Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening~* Presence of surgical hardware or other foreign body in the index knee~* Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months of Screening~* IA corticosteroid (investigational or marketed) in index knee within 3 months of Screening~* IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening~* IV or intramuscular (IM) corticosteroids (investigational or marketed) within 3 months of Screening~* Oral corticosteroids (investigational or marketed) within 1 month of Screening~* Any other IA drug/biologic use within 6 months of Screening or 5 half-lives (whichever is longer) (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy and amniotic fluid injection)~* Prior administration of FX006~* Women of child-bearing potential not using effective contraception or who are pregnant or nursing

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FX006 32 mg (Type: EXPERIMENTAL): Single intra-articular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).